SGLT2i, Hepatic Glucose Production, and SNS

In this study, PI will test the hypothesis that distinct mechanisms account for the SGLT2i-induced stimulation of ketogenesis and lipolysis versus endogenous (hepatic) glucose production in patients with type 2 diabetes (T2D) that the increases in ketone production and lipolysis can be prevented by concomitant administration of the thiazolidinedione pioglitazone. Principal Investigator (PI) will conduct five distinct experiments to test this hypothesis in patients with T2D. To examine the role of the SNS on the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D by comparing the effect of empagliflozin versus empagliflozin plus propranolol.

NCT Number	NCT07053293
Lead Sponsor	The University of Texas Health Science Center at San Antonio Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions	Type 2 Diabetes
Enrollment	22 participants
Start Date	2025-01-07
Primary Completion	2027-06-01 (estimated)
Study Completion	2027-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-17